Agios Pharmaceuticals Inc (NASDAQ:AGIO) Receives Consensus Rating of “Hold” from Analysts

Agios Pharmaceuticals Inc (NASDAQ:AGIO) has earned an average recommendation of “Hold” from the thirteen brokerages that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $62.43.

Several research firms have recently weighed in on AGIO. Piper Jaffray Companies set a $80.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 24th. Royal Bank of Canada lowered their price target on shares of Agios Pharmaceuticals to $82.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. Guggenheim raised shares of Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $55.00 price target for the company in a report on Monday, September 23rd. BMO Capital Markets started coverage on shares of Agios Pharmaceuticals in a report on Thursday, September 12th. They issued an “outperform” rating and a $45.00 price target for the company. Finally, Cowen reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Monday, September 30th.

Shares of NASDAQ AGIO traded down $0.23 during mid-day trading on Wednesday, hitting $33.93. 16,125 shares of the stock were exchanged, compared to its average volume of 665,676. The company has a market cap of $2.01 billion, a P/E ratio of -5.64 and a beta of 2.31. The stock’s fifty day simple moving average is $37.30 and its two-hundred day simple moving average is $48.30. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.91 and a current ratio of 5.96. Agios Pharmaceuticals has a twelve month low of $31.46 and a twelve month high of $74.25.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($0.17). The firm had revenue of $26.22 million for the quarter, compared to analyst estimates of $27.05 million. Agios Pharmaceuticals had a negative return on equity of 59.89% and a negative net margin of 383.05%. The business’s quarterly revenue was down 35.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.19) EPS. As a group, equities research analysts predict that Agios Pharmaceuticals will post -7.13 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System boosted its position in shares of Agios Pharmaceuticals by 0.4% during the first quarter. California State Teachers Retirement System now owns 80,018 shares of the biopharmaceutical company’s stock worth $5,396,000 after purchasing an additional 334 shares in the last quarter. US Bancorp DE boosted its position in shares of Agios Pharmaceuticals by 82.6% during the second quarter. US Bancorp DE now owns 1,010 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 457 shares in the last quarter. NumerixS Investment Technologies Inc bought a new position in shares of Agios Pharmaceuticals during the second quarter worth $35,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Agios Pharmaceuticals by 27.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,666 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 779 shares in the last quarter. Finally, Capital International Ltd. CA boosted its position in shares of Agios Pharmaceuticals by 6.7% during the second quarter. Capital International Ltd. CA now owns 13,465 shares of the biopharmaceutical company’s stock worth $672,000 after purchasing an additional 847 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Featured Story: What is a closed-end mutual fund (CEF)?

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.